Document:

Exhibit 10.1

 

CONVERTIBLE NOTE PURCHASE AGREEMENT

 

This Convertible
Note Purchase Agreement (the “Agreement”) is made and entered into as of March 15, 2013 by
and among Nile Therapeutics, Inc., a Delaware corporation (the “Company”), and the individuals and/or
entities listed on Exhibit A attached hereto (each, a “Purchaser,” collectively,
the “Purchasers”).

 

A.           The
Company currently requires funds to help finance its operations as it pursues either a strategic transaction or a subsequent financing.

 

B.           The
Purchasers are willing to advance funds to the Company in exchange for the issuance to them of certain convertible promissory notes
evidencing the Company’s obligation to repay the Purchasers’ loans of the advanced funds, all as provided in this Agreement.

 

NOW THEREFORE, the parties hereby agree
as follows:

 

Article
1

 

PURCHASE, SALE AND TERMS OF NOTES

 

1.01         The
Notes. The Company has authorized the issuance and sale to the Purchasers of the Company’s
Convertible Promissory Notes in the original aggregate principal amount of up to $500,000 as set forth on Exhibit A
hereto. The Convertible Promissory Notes shall be substantially in the form set forth as Exhibit B
hereto and are herein referred to individually as a “Note” and collectively as the “Notes,”
which terms shall also include any notes delivered in exchange or replacement therefor.

 

1.02         Security
Agreement. The Notes will be secured by a general security interest in the Company’s
tangible and intangible assets. Such security interest shall be evidenced by a security agreement among the Company and the Purchase
in substantially the form attached hereto as Exhibit C (the “Security
Agreement”), to be executed and delivered at the Closing (as defined below).

 

1.03         Purchase
and Sale of Notes – Closing. The Company agrees to issue and sell to the Purchasers,
and, subject to and in reliance upon the representations, warranties, covenants, terms and conditions of this Agreement, the Purchasers
agree to purchase the Notes in the principal amounts set forth opposite each Purchaser’s name on Exhibit A
hereto under the heading “Principal Amount of Notes To Be Purchased at the Closing.” Such purchase and sale shall take
place at a closing (the “Closing”) to be held remotely via the exchange of documents and signatures,
on the date hereof at 12:00 a.m., California time, or at such other time or place as may be mutually agreed upon by the
Company and the Purchasers purchasing at least two thirds of the principal amount of the Notes to be purchased at the Closing (the
“Requisite Purchasers”). At the Closing, each Purchaser will deliver to the Company as payment in full
for the Note to be purchased by such Purchaser at the Closing, the amount set forth opposite such Purchaser’s name in the
“Purchase Price” column on Exhibit A, by wire transfer
or other delivery of immediately available funds to the Company. At the Closing, the Company will issue and deliver to each Purchaser
a duly executed Note in the principal amount set forth opposite such Purchaser’s name on Exhibit A.
The Company shall send such Notes to such Purchaser at the address furnished to the Company for that purpose.

 

    	 

    	 

    

 

1.04         Registration
Rights. The Company agrees to register the resale of the Conversion Shares and Warrant
Shares (each as defined in the Notes), if applicable, under the Securities Act on Form S-1 or any other appropriate form in the
sole discretion of the Company (the “Registration Statement”). The Company shall use its commercially
reasonable efforts to file the Registration Statement with the U.S. Securities and Exchange Commission (the “Commission”)
within 60 days following the issuance of the Conversion Shares.

 

1.05         No
Usury. This Agreement and each Note issued pursuant to the terms of this Agreement
are hereby expressly limited so that in no event whatsoever, whether by reason of deferment or advancement of loan proceeds, acceleration
of maturity of the loan evidenced hereby, or otherwise, shall the amount paid or agreed to be paid to the Purchasers hereunder
for the loan, use, forbearance or detention of money exceed the maximum interest rate permitted by the laws of the State of California.
If at any time the performance of any provision hereof or any Note involves a payment exceeding the limit of the price that may
be validly charged for the loan, use, forbearance or detention of money under applicable law, then automatically and retroactively,
ipso facto, the amount payable under the Notes shall be reduced to such limit. The provisions of this Section 1.05 shall never
be superseded or waived and shall control every other provision of this Agreement and any Note.

 

Article
2

 

CONDITIONS TO PURCHASERS’ OBLIGATIONS

 

The respective and several obligations of
each Purchaser to purchase and pay for the Notes to be purchased by it at the Closing are subject to the fulfillment or waiver,
on or before the Closing, of each of the following conditions:

 

2.01         Representations
and Warranties. Each of the representations and warranties of the Company set forth
in Article 3 hereof shall be true in all material respects on the date of the Closing.

 

2.02         Performance
by the Company. The Company shall have performed and complied with all agreements,
obligations and conditions contained in this Agreement that are required to be performed or complied with by it on or before the
Closing and shall have obtained all approvals, consents and qualifications necessary to complete the purchase and sale described
herein.

 

2.03         Delivery
of Notes. The Company shall have executed and delivered to each Purchaser a Note,
in the form attached hereto as Exhibit B, evidencing the Company’s
indebtedness to such Purchaser in the amount next to such Purchaser’s name on Exhibit A
under the heading “Principal Amount of Notes To Be Purchased at the Closing.”

 

2.04         Delivery
of Security Agreement. The Company shall have executed and delivered to each Purchaser
the Security Agreement, in the form attached hereto as Exhibit C. 

 

    	2

    	 

    

 

Article
3

 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

 

The Company represents and warrants to each
of the Purchasers as follows, each of which representation and warranty is true and correct as of the Closing:

 

3.01         Organization,
Qualifications and Corporate Power. The Company is a corporation duly incorporated,
validly existing and in good standing under the laws of the State of Delaware and is duly licensed or qualified to transact
business as a foreign corporation and is in good standing in each jurisdiction in which the nature of the business transacted by
it or the character of the properties owned or leased by it requires such licensing or qualification, except where the failure
to be so licensed or qualified would not have a Material Adverse Effect (as defined below) on the business or assets of the Company.
“Material Adverse Effect” shall mean any event, change, violation,
inaccuracy, circumstance or effect that is, individually or in the aggregate, materially adverse to the financial condition, capitalization,
properties, employees, assets (including intangible assets), business, operations or results of operations of the Company. The
Company has the corporate power and authority to own and hold its properties and to carry on its business as now conducted and
as presently proposed to be conducted, to execute, deliver and perform this Agreement and to issue, sell and deliver the Notes.

 

3.02         Authorization
of Agreements, Etc. The execution and delivery by the Company of this Agreement and
the performance by the Company of its obligations hereunder and the issuance, sale and delivery of the Notes have been duly authorized
by all requisite corporate action and will not violate any provision of law, any order of any court or other agency of government,
the Certificate of Incorporation of the Company, or the bylaws of the Company, nor will such actions result in a violation of any
provision of any indenture, agreement or other instrument to which the Company, or any of its properties or assets is bound, or
conflict with, result in a material breach of or constitute (with due notice or lapse of time or both) a default under any such
indenture, agreement or other instrument, or result in the creation or imposition of any lien, charge, restriction, encumbrance,
or, to the Company’s knowledge, claim of any nature whatsoever upon any of the properties or assets of the Company, the result
of any of which would have a Material Adverse Effect.

 

3.03         Validity.
This Agreement has been duly executed and delivered by the Company and constitutes the valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms. The Notes and the Security Agreement, when executed and delivered
in accordance with this Agreement, will constitute the valid and binding obligations of the Company, enforceable against the Company
in accordance with their respective terms. The Warrants (as defined in the Notes), when executed and delivered in accordance with
the terms of the Notes, will constitute the valid and binding obligations of the Company, enforceable against the Company in accordance
with their respective terms. The Conversion Shares and Warrant Shares, when issued, sold and delivered in accordance with the terms
of the Notes and the Warrants, respectively, for the consideration provided for herein and therein, will be duly and validly issued,
fully paid and nonassessable. 

 

    	3

    	 

    

 

Article
4

 

REPRESENTATIONS AND WARRANTIES OF PURCHASERS

 

Each Purchaser represents and warrants to
the Company that: (a) it has full power and authority to enter into and perform this Agreement in accordance with its terms,
and it was not organized for the specific purpose of acquiring the Notes, the Warrants, the Conversion Shares, or the Warrant Shares
(collectively, the “Securities”); (b) it has sufficient knowledge and experience in investing in
companies similar to the Company in terms of the Company’s stage of development so as to be able to evaluate the risks and
merits of its investment in the Company and it is able financially to bear the risks thereof; (c) it has made an investigation
of the Company and its business as it deemed necessary and has had an opportunity to review all reports, schedules, forms, statements
and other documents filed by the Company with the Commission, including the exhibits thereto and documents incorporated by reference
therein, and to discuss and review the Company’s business, management and financial affairs with the Company’s management
as it deemed necessary; (d) the Securities being purchased by it are being acquired for its own account for the purpose of
investment and not with a view to the public resale or distribution thereof within the meaning of the Securities Act of 1933, as
amended (the “Securities Act”); (e) it understands that (i) the Securities have not been registered
under the Securities Act by reason of their issuance in a transaction exempt from the registration requirements of the Securities
Act pursuant to Section 4(2) thereof or Rule 504, 505 or 506 promulgated under the Securities Act, (ii) under
the Securities Act and applicable regulations thereunder the Securities may be resold without registration under the Securities
Act only in certain limited circumstances, (iii) the certificates evidencing the Securities will bear a legend substantially
similar to that set forth below:

 

THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF APPLICABLE STATES. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE
TRANSFERRED OR RESOLD EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION UNDER SUCH
LAWS OR AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENT. INVESTORS SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL
RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL IN
FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER TO THE EFFECT THAT ANY PROPOSED TRANSFER OR RESALE IS IN COMPLIANCE WITH THE ACT
AND ALL APPLICABLE STATE SECURITIES LAWS.

 

and (iv) the Company will make a notation on its transfer
books to such effect; (f) this Agreement has been duly executed and delivered by it and constitutes the legal, valid and binding
obligation of it, enforceable in accordance with the terms of the Agreement; and (g) it is an “accredited investor”
as that term is defined in Rule 501 promulgated under the Securities Act.

 

    	4

    	 

    

  

Article
5

 

MISCELLANEOUS

 

5.01         No
Waiver; Cumulative Remedies. No failure or delay on the part of any party to this
Agreement in exercising any right, power or remedy hereunder shall operate as a waiver thereof; nor shall any single or partial
exercise of any such right, power or remedy preclude any other or further exercise thereof or the exercise of any other right,
power or remedy hereunder. The remedies herein provided are cumulative and not exclusive of any remedies provided by law.

 

5.02         Amendments,
Waivers and Consents. Any provision in this Agreement to the contrary notwithstanding,
changes in or additions to this Agreement or the Notes may be made, and compliance with any covenant or provision herein or therein
set forth may be omitted or waived, if the Company shall obtain consent thereto in writing from the Requisite Purchasers. Any amendment
or waiver effected in accordance with this Section 5.02 shall be binding upon each holder of Notes then outstanding, each future
holder of such securities, and the Company; provided, however, that no amendment shall be effective against a Purchaser which materially
and adversely affects such Purchaser’s rights under this Agreement or under any Notes in a manner that is adverse to and
materially different from the effect on other Purchasers of Notes, without such Purchaser’s written consent.

 

5.03         Addresses
for Notices, etc. Any notice required or permitted hereunder shall be given in writing
and shall be conclusively deemed effectively given upon personal delivery or delivery by courier, or on the first (1st)
business day after transmission if sent by confirmed facsimile transmission, or four (4) business days after deposit in U.S. mail,
by registered or certified mail, postage prepaid, addressed (i) if to the Company, as set forth below the Company’s name
on the signature page of this Agreement, and (ii) if to a Purchaser, as set forth below such Purchaser’s name on the respective
signature page of this Agreement, or at such other address as the Company or such Purchaser may designate by advance written notice
to the other parties hereto. For purposes of this Section 5.03, a “business day” means a weekday on which
banks are open for general banking business in New York City, New York.

 

5.04         Binding
Effect; Assignment. The terms and conditions of this Agreement shall be binding upon
and inure to the benefit of the Company and the Purchasers and their respective heirs, successors and assigns.

 

5.05         Headings;
Interpretation. In this Agreement, (i) the meaning of defined terms shall be
equally applicable to both the singular and plural forms of the terms defined; (ii) the captions and headings are used only
for convenience and are not to be considered in construing or interpreting this Agreement and (iii) the words “including,”
“includes” and “include” shall be deemed to be followed by the words “without limitation”.
All references in this Agreement to sections, paragraphs, exhibits and schedules shall, unless otherwise provided, refer to sections
and paragraphs hereof and exhibits and schedules attached hereto, all of which exhibits and schedules are incorporated herein by
this reference.

 

    	5

    	 

    

 

5.06         No
Finder’s Fees. Each party represents that it neither is nor will be obligated
for any finder’s or broker’s fee or commission in connection with the transactions contemplated by this Agreement.
Each Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the
nature of a finder’s or broker’s fee (and any asserted liability) for which the Purchaser or any of its directors,
officers, partners, members, employees or representatives is responsible. The Company agrees to indemnify and hold harmless each
Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee (and any
asserted liability) for which the Company or any of its officers, employees or representatives is responsible.

 

5.07         Survival
of Representations and Warranties. All representations and warranties made in this
Agreement and the Notes or any other instrument or document delivered in connection herewith or therewith, shall survive the execution
and delivery hereof or thereof, and the Closing, and shall in no way be affected by any investigation of the subject matter thereof
made by or on behalf of any of the Purchasers or the Company, as the case may be.

 

5.08         Severability.
The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

 

5.09         Governing
Law. This Agreement shall be governed by, and construed in accordance with, the Delaware
General Corporation Law as to matters within the scope thereof, and as to all other matters shall be governed by, and construed
in accordance with, the internal laws of the State of Delaware, without reference to principles of conflict of laws or choice of
laws.

 

5.10         Counterpart;
Facsimile Signatures. This Agreement may be executed in any number of counterparts,
each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument, and any
of the parties hereto may execute this Agreement by signing any such counterpart. This Agreement may be executed and delivered
by facsimile, or by e-mail in portable document format (.pdf) and delivery of the signature page by such method will be deemed
to have the same effect as if the original signature had been delivered to the other parties.

 

5.12         Entire
Agreement. This Agreement and the other documents delivered at the Closing constitute the full and entire understanding and
agreement between the parties with respect to the subject matter hereof and supersede all prior agreements with respect to the
subject matter hereof.

 

5.13         Further
Assurances. From and after the date of this Agreement, upon the request of any Purchaser or the Company, the Company and the
Purchasers shall execute and deliver such instruments, documents or other writings as may be reasonably necessary or desirable
to confirm and carry out and to effectuate fully the intent and purposes of this Agreement.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT
BLANK]

 

    	6

    	 

    

 

SIGNATURE PAGE

 

Principal Amount of Note = _______________

 

Purchase Price of Note = ________________

 

Name in which securities should be issued: _________________________________________________________

 

	 	 	 
	Signature	 	Signature (if purchasing jointly)
	 	 	 
	 	 	 
	Name Typed or Printed	 	Name Typed or Printed
	 	 	 
	 	 	 
	Entity Name	 	Entity Name
	 	 	 
	 	 	 
	Address	 	Address
	 	 	 
	 	 	 
	City, State and Zip Code	 	City, State and Zip Code
	 	 	 
	 	 	 
	Telephone	 	Telephone
	 	 	 
	 	 	 
	Facsimile	 	Facsimile
	 	 	 
	 	 	 
	Tax ID # or Social Security #	 	Tax ID # or Social Security #

 

Dated: March ____, 2013

 

COMPANY

 

This Convertible Note Purchase Agreement is agreed to and accepted
as of March ____, 2013.

 

	 	NILE THERAPEUTICS, INC.
	 	 	 
	 	By:	 	 
	 	Name:	Darlene Horton, M.D.
	 	Title:	Chief Executive Officer

 

Signature Page to Convertible Note Purchase Agreement

 

    	 

    	 

    

 

EXHIBIT A

 

Schedule of Purchasers

 

	Purchaser	 	Principal Amount of Notes To
 Be Purchased at Closing	 	 	Purchase Price
 (85% of Principal Amount)	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Total 
	 	$	450,000	 	 	$	382,500	 

 

    	 

    	 

    

 

EXHIBIT B

 

Form of Convertible Promissory Note

 

    	 

    	 

    

 

EXHIBIT C

 

Form of Security AgreementExhibit 10.2

 

SECURITY AGREEMENT

 

This SECURITY AGREEMENT
(this “Agreement”) is made as of March 15, 2013, among Nile Therapeutics, Inc., a Delaware corporation (the
“Company”), and the creditors identified in Attachment A hereto, as the same may be supplemented or amended
from time to time (collectively, the “Creditors,” and each individually, a “Creditor”), which
includes all purchasers of convertible promissory notes sold by the Company pursuant to that certain Convertible Note Purchase
Agreement dated March 15, 2013 (the “Purchase Agreement”).

 

WHEREAS, the Creditors
have made loans to the Company in the respective amounts set forth opposite each Creditor’s name on Attachment A and have
received from the Company promissory notes in such amounts (the “Notes”); and

 

WHEREAS, the Company
has agreed to secure the payment of the Notes by pledging, as security therefore, certain assets owned by the Company.

 

NOW, THEREFORE, in
consideration of the mutual covenants and agreements contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which is hereby acknowledged, the Company and each Creditor agree as follows:

 

1.     Grant
of Security Interest.

 

(a)          To
secure payment and performance of the Obligations (as defined below), the Company hereby grants to the Creditors a security interest
in all property and interests in property of the Company, whether now owned or hereafter acquired or existing, and wherever located
(together with all other collateral security for the Obligations at any time granted to or held or acquired by the Creditors, collectively,
the “Collateral”), including, without limitation, the following: (i) all Accounts; (ii) all Receivables; (iii)
all Equipment; (iv) all General Intangibles; (v) all Inventory; (vi) all Investment Property; and (vii) all proceeds and products
of (i), (ii), (iii), (iv), (v) and (vi).

 

(b)          Notwithstanding
anything to the contrary contained in Section 1(a) above, the types or items of Collateral described in such Section
1(a) shall not include any right or interest in any contract, permit or application covering real or personal property of the
Company, as such, if under the terms of such contract, permit or application or applicable law with respect thereto, the valid
grant of a security interest to the Creditors is prohibited as a matter of law or under the terms thereof and such prohibition
has not been or is not waived or the consent of the other party to such contract, permit, or application has not been or is not
otherwise obtained; provided, that, the foregoing exclusion shall in no way be construed (i) to apply if any such
prohibition is unenforceable under the UCC or other applicable law or (ii) so as to limit, impair or otherwise affect the Creditors’
unconditional continuing security interest in upon any rights or interests of the Company in or to monies due or to become due
under any such contract, permit or application.

 

(c)          Perfection
of Security Interests.

 

(i)          As
soon as practicable following the execution of this Agreement, the Company shall file UCC financing statements in all appropriate
jurisdictions to record the security interests granted to the Creditors hereunder. Without the prior written consent of the Requisite
Purchasers (as defined in the Purchase Agreement), the Company shall not at any time file, or permit or cause to be filed, any
correction statement or termination statement with respect to any financing statement (or amendment or continuation with respect
thereto) naming the Creditors or their designee(s) as secured party and the Company or any affiliate of the Company as debtor.

 

    	 

    	 

    

 

(ii)         The
Company shall take any other actions reasonably requested by the Creditors from time to time to cause the attachment and perfection
of, and the ability of the Creditors to enforce, the security interest of the Creditors in the Collateral.

 

2.     Covenants
Relating to Collateral. The Company covenants that:

 

(a)          it
shall at all times be the sole owner of each and every item of Collateral, except with respect to licensed intellectual property
or as otherwise disclosed in reports filed by the Company with the Securities and Exchange Commission prior to the date hereof;

 

(b)          it
shall defend the Collateral against the claims and demands of all persons;

 

(c)          it
will comply with the requirements of all agreements relating to premises where any Collateral is located;

 

(d)          it
will give the Creditors twenty (20) days’ prior written notice of any change to its name;

 

(e)          it
will give the Creditors twenty (20) days’ prior written notice of any change to its chief executive office or its mailing
address; and

 

(f)          it
will give the Creditors twenty (20) days’ prior written notice of any change to its type of organization, jurisdiction of
organization or other legal structure.

 

3.     Remedies.
Upon the occurrence and after the continuance of an Event of Default (as defined in the Notes), (i) the Creditors shall have the
right to exercise any right and remedy provided for herein, under the UCC and at law or equity generally, including, without limitation,
the right to foreclose the security interests granted herein and to realize upon any Collateral by any available judicial procedure
and/or to take possession of and sell any or all of the Collateral with or without judicial process; and (ii) with or without having
the Collateral at the time or place of sale, the Creditors may sell the Collateral, or any part thereof, at public or private sale,
at any time or place, in one or more sales, at such price or prices, and upon such terms, either for cash, credit or future delivery,
as the Creditors may elect.

 

4.     Pro-Rata
Payments and Forbearance. Each Creditor agrees not to accept payments with respect to the Notes other than on a pro-rata basis
as set forth in Attachment A. In the event that one or more of the Creditors shall receive preferential payments with respect to
the Notes, the recipient Creditor shall undertake to redistribute to the other Creditors any amounts of such payments as shall
be necessary to maintain pro-rata payments to all Creditors with respect to the Notes.

 

5.     Priority.
All of the Creditors agree that, notwithstanding the date, manner or order of attachment or perfection of any security interest
and regardless of any priority otherwise available by law or by agreement, the Creditors’ security interest in the Collateral
shall be of equal priority, and any recovery by any Creditor of the Collateral shall be shared ratably in proportion to the respective
amounts of the Notes then due and owing to the Creditors.

 

6.     Representations
and Warranties. The Company hereby represents and warrants to the Creditors that:

 

(a)          The
Company is a corporation duly organized and validly existing under the laws of Delaware.

 

(b)          The
exact legal name of the Company is as set forth on the signature page of this Agreement.

 

    	2

    	 

    

 

(c)          The
chief executive office and mailing address of the Company are located at the address set forth in Section 11 and its only
other places of business and the only other locations of Collateral, if any, are at the addresses set forth on Schedule 6(c).

 

7.     Expenses
of the Company; Creditors’ Right to Perform on the Company’s Behalf. 

 

(a)          The
Company’s agreements hereunder shall be performed by it at its sole cost and expense.

 

(b)          If
the Company shall fail to do any act which it has covenanted to do hereunder, the Creditors may (but shall not be obligated to)
do the same or cause it to be done, either in their name or in the name and on behalf of the Company, and the Company hereby irrevocably
authorizes the Creditors so to act.

 

8.     No
Waivers of Rights hereunder; Rights Cumulative.

 

(a)          No
delay by the Creditors in exercising any right hereunder, or in enforcing any of the Obligations, shall operate as a waiver thereof,
nor shall any single or partial exercise of any right preclude other or further exercises thereof or the exercise of any other
right. No waiver of any of the Obligations shall be enforceable against any Creditor unless in writing and signed by such Creditor,
and unless it expressly refers to the provision affected; any such waiver shall be limited solely to the specific event waived.

 

(b)          All
rights granted to the Creditors hereunder shall be cumulative and shall be supplementary of and in addition to those granted or
available to the Creditors under any other agreement with respect to the Obligations or under applicable law and nothing herein
shall be construed as limiting any such other right.

 

9.     Termination.
This Agreement shall continue in full force and effect until all Obligations shall have been
paid and satisfied in full.

 

10.   Additional
Definitions. As used herein:

 

(a)          All
terms used herein which are defined in Article 1 or Article 9 of the UCC shall have the meanings given therein unless otherwise
defined in this Agreement. All references to the plural herein shall also mean the singular and to the singular shall also mean
the plural unless the context otherwise requires. All references to the Company and the Creditors pursuant to the definitions set
forth in the recitals hereto, or to any other person herein, shall include their respective successors and assigns. The words “hereof”,
“herein”, “hereunder”, “this Agreement” and words of similar import when used in this Agreement
shall refer to this Agreement as a whole and not any particular provision of this Agreement and as this Agreement now exists or
may hereafter be amended, modified, supplemented, extended, renewed, restated or replaced. The word “including” when
used in this Agreement shall mean “including, without limitation”. The words “it” or “its”
as used herein shall be deemed to refer to individuals and to business entities.

 

    	3

    	 

    

 

(b)          “Obligations”
means:

 

(i)          the
full and prompt payment by the Company when due of all obligations and liabilities to the Creditors, whether now existing or hereafter
arising, under the Notes and the due performance and compliance by the Company with the terms thereof;

 

(ii)         any
and all sums advanced in accordance with applicable law by the Creditors in order to preserve the Collateral or to preserve the
Creditors’ security interest in the Collateral; and

 

(iii)        in
the event of any proceeding for the collection or enforcement of any obligations or liabilities of the Company referred to in the
immediately preceding clauses (i) and (ii), the reasonable expenses of re-taking, holding, preparing for sale, selling or otherwise
disposing of or realizing on the Collateral, or of any other exercise by the Creditors of their rights hereunder, together with
reasonable attorneys’ fees and court costs.

 

(c)          “Person”
or “person” shall mean any individual, sole proprietorship, partnership, corporation limited liability company,
limited liability partnership, business trust, unincorporated association, joint stock corporation, trust, joint venture or other
entity or any government or any agency or instrumentality or political subdivision thereof.

 

(d)          “UCC”
shall mean the Uniform Commercial Code as in effect in the State of Delaware and any successor statute, as in effect from time
to time (except that terms used herein which are defined in the Uniform Commercial Code as in effect in the State of Delaware on
the date hereof shall continue to have the same meaning notwithstanding any replacement or amendment of such statute except as
the Creditors may otherwise determine).

 

11.   Notices. Any
communication required or permitted pursuant to this Agreement shall be deemed given (a) when personally delivered to any
officer of the party to whom it is addressed, (b) on the earlier of actual receipt thereof or five (5) days following posting
thereof by certified or registered mail, postage prepaid, return receipt requested, or (c) upon actual receipt thereof when
sent by a recognized overnight delivery service, or (d) upon actual receipt thereof when sent by fax to the number set forth
below with telephone communication confirming receipt and subsequently confirmed by registered or certified mail, return
receipt requested, or by recognized overnight delivery service to the address set forth below, in each case addressed to the
applicable party at its address set forth below or at such other address as has been furnished in writing by such party to
the other by like notice:

 

If to the Company:

 

Nile Therapeutics,
Inc.

4 West 4th Ave.,
Suite 400

San Mateo, CA
94402

Tel: (650) 458-2670

Fax: (415) 875-7075

Attn: Chief Executive
Officer

 

If to a Creditor, to such address as such
Creditor shall have provided to the Company in the Purchase Agreement, as may be amended hereafter by written notice by such Creditor
to the Company delivered as aforesaid; or, in any case, at such other address or addresses as shall have been furnished in writing
by such party to the other party.

    	4

    	 

    

 

Any requirement under
applicable law of reasonable notice by the Creditors to the Company of any event shall be met if notice is given to the Company
in the manner prescribed above at least five (5) days before (a) the date of such event or (b) the date after which such event
will occur.

 

12.   Governing
Law. This Agreement shall be construed and enforced in accordance with, and the rights of the parties shall be governed by,
the laws of the State of Delaware, without regard to the conflicts of laws provisions thereof.

 

13.   Counterparts.
This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together
constitute one and the same instrument.

 

14.   Successors
and Assigns. This Agreement shall be binding upon the assigns or successors of the Company and shall inure to the benefit of
and be enforceable by the Creditors and their successors, transferees and assigns.

 

15.   Severability.
Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective
to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof in that jurisdiction
or affecting the validity or enforceability of such provision in any other jurisdiction.

 

Remainder of page intentionally left
blank

 

    	5

    	 

    

 

 

IN WITNESS WHEREOF,
the parties hereto have executed this Agreement in counterparts.

 

	 	NILE THERAPEUTICS, INC.
	 	 	 
	 	By:	 
	 	Name:	Darlene Horton, M.D.
	 	Title:	Chief Executive Officer

 

Signature Page to Security Agreement

Signature Pages Continue

  

    	 

    	 

    

 

Creditor:

 

If the undersigned is an individual
(not a partnership, corporation, etc.):

 

	 	 
	Please Print Name	 
	 	 
	 	 
	Signature	 
	 	 
	 	 
	Date	 
	 	 
	 	 
	Please Print Name of Joint Holder (if any)	 
	 	 
	 	 
	Signature	 
	 	 
	 	 
	Date	 
	 	 
	If the undersigned is a corporation, partnership or other legal entity:
	 	 
	 	 
	Please Print Name of Entity	 
	 	 
	By:	 	 
	Name:	 
	Title:	 
	 	 
	 	 
	Date	 
	 	 	 

Signature Page to Security Agreement

Signature Pages Continue

  

    	 

    	 

    

 

Creditor:

 

If the undersigned is an individual
(not a partnership, corporation, etc.):

 

	 	 
	Please Print Name	 
	 	 
	 	 
	Signature	 
	 	 
	 	 
	Date	 
	 	 
	 	 
	Please Print Name of Joint Holder (if any)	 
	 	 
	 	 
	Signature	 
	 	 
	 	 
	Date	 
	 	 
	If the undersigned is a corporation, partnership or other legal entity:
	 	 
	 	 
	Please Print Name of Entity	 
	 	 
	By:	 	 
	Name:	 
	Title:	 
	 	 
	 	 
	Date	 
	 	 	 

Signature Page to Security Agreement

 

    	 

    	 

    

 

ATTACHMENT A

TO

SECURITY AGREEMENT

 

	Creditor Name	Principal Amount of Promissory Note
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 
	 	 

  

    	 

    	 

    

 

SCHEDULE 6(c)

TO

SECURITY AGREEMENT

 

None.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00214-of-00352.parquet"}]]